312 related articles for article (PubMed ID: 18023977)
1. PLGA, chitosan or chitosan-coated PLGA microparticles for alveolar delivery? A comparative study of particle stability during nebulization.
Manca ML; Mourtas S; Dracopoulos V; Fadda AM; Antimisiaris SG
Colloids Surf B Biointerfaces; 2008 Apr; 62(2):220-31. PubMed ID: 18023977
[TBL] [Abstract][Full Text] [Related]
2. Release of rifampicin from chitosan, PLGA and chitosan-coated PLGA microparticles.
Manca ML; Loy G; Zaru M; Fadda AM; Antimisiaris SG
Colloids Surf B Biointerfaces; 2008 Dec; 67(2):166-70. PubMed ID: 18835764
[TBL] [Abstract][Full Text] [Related]
3. Liposomes for drug delivery to the lungs by nebulization.
Zaru M; Mourtas S; Klepetsanis P; Fadda AM; Antimisiaris SG
Eur J Pharm Biopharm; 2007 Nov; 67(3):655-66. PubMed ID: 17540552
[TBL] [Abstract][Full Text] [Related]
4. Formulation and in vitro characterization of inhalable rifampicin-loaded PLGA microspheres for sustained lung delivery.
Doan TV; Couet W; Olivier JC
Int J Pharm; 2011 Jul; 414(1-2):112-7. PubMed ID: 21596123
[TBL] [Abstract][Full Text] [Related]
5. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model.
Suarez S; O'Hara P; Kazantseva M; Newcomer CE; Hopfer R; McMurray DN; Hickey AJ
Pharm Res; 2001 Sep; 18(9):1315-9. PubMed ID: 11683246
[TBL] [Abstract][Full Text] [Related]
6. Efficient intracellular delivery of rifampicin to alveolar macrophages using rifampicin-loaded PLGA microspheres: effects of molecular weight and composition of PLGA on release of rifampicin.
Makino K; Nakajima T; Shikamura M; Ito F; Ando S; Kochi C; Inagawa H; Soma G; Terada H
Colloids Surf B Biointerfaces; 2004 Jul; 36(1):35-42. PubMed ID: 15261021
[TBL] [Abstract][Full Text] [Related]
7. One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis.
Ohashi K; Kabasawa T; Ozeki T; Okada H
J Control Release; 2009 Apr; 135(1):19-24. PubMed ID: 19121349
[TBL] [Abstract][Full Text] [Related]
8. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
Pandey R; Sharma A; Zahoor A; Sharma S; Khuller GK; Prasad B
J Antimicrob Chemother; 2003 Dec; 52(6):981-6. PubMed ID: 14613962
[TBL] [Abstract][Full Text] [Related]
9. Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions.
Yamamoto H; Kuno Y; Sugimoto S; Takeuchi H; Kawashima Y
J Control Release; 2005 Feb; 102(2):373-81. PubMed ID: 15653158
[TBL] [Abstract][Full Text] [Related]
10. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization.
O'Hara P; Hickey AJ
Pharm Res; 2000 Aug; 17(8):955-61. PubMed ID: 11028941
[TBL] [Abstract][Full Text] [Related]
11. Chitosan-coated liposomes for delivery to lungs by nebulisation.
Zaru M; Manca ML; Fadda AM; Antimisiaris SG
Colloids Surf B Biointerfaces; 2009 Jun; 71(1):88-95. PubMed ID: 19201583
[TBL] [Abstract][Full Text] [Related]
12. Preparation of sustained release rifampicin microparticles for inhalation.
Son YJ; McConville JT
J Pharm Pharmacol; 2012 Sep; 64(9):1291-302. PubMed ID: 22881441
[TBL] [Abstract][Full Text] [Related]
13. Influence of post-emulsification drying processes on the microencapsulation of human serum albumin.
Lane ME; Brennan FS; Corrigan OI
Int J Pharm; 2006 Jan; 307(1):16-22. PubMed ID: 16274944
[TBL] [Abstract][Full Text] [Related]
14. In vivo evaluation of solid lipid microparticles and hybrid polymer-lipid microparticles for sustained delivery of leuprolide.
Wu C; Luo X; Baldursdottir SG; Yang M; Sun X; Mu H
Eur J Pharm Biopharm; 2019 Sep; 142():315-321. PubMed ID: 31299277
[TBL] [Abstract][Full Text] [Related]
15. Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug.
Sethuraman VV; Hickey AJ
AAPS PharmSciTech; 2002; 3(4):E28. PubMed ID: 12916922
[TBL] [Abstract][Full Text] [Related]
16. The development and mechanism studies of cationic chitosan-modified biodegradable PLGA nanoparticles for efficient siRNA drug delivery.
Yuan X; Shah BA; Kotadia NK; Li J; Gu H; Wu Z
Pharm Res; 2010 Jul; 27(7):1285-95. PubMed ID: 20309616
[TBL] [Abstract][Full Text] [Related]
17. Rifampicin polylactic acid microspheres for lung targeting.
Zhang W; Jiang X; Hu J; Fu C
J Microencapsul; 2000; 17(6):785-8. PubMed ID: 11063425
[TBL] [Abstract][Full Text] [Related]
18. Airways delivery of rifampicin microparticles for the treatment of tuberculosis.
Suarez S; O'Hara P; Kazantseva M; Newcomer CE; Hopfer R; McMurray DN; Hickey AJ
J Antimicrob Chemother; 2001 Sep; 48(3):431-4. PubMed ID: 11533012
[TBL] [Abstract][Full Text] [Related]
19. Water-soluble betamethasone-loaded poly(lactide-co-glycolide) hollow microparticles as a sustained release dosage form.
Chaw CS; Yang YY; Lim IJ; Phan TT
J Microencapsul; 2003; 20(3):349-59. PubMed ID: 12881115
[TBL] [Abstract][Full Text] [Related]
20. Lipid and PLGA Microparticles for Sustained Delivery of Protein and Peptide Drugs.
Wu C; Mu H
Pharm Nanotechnol; 2020; 8(1):22-32. PubMed ID: 31663483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
